Adagio Medical, Inc., a leading innovator in catheter ablation technologies for ventricular tachycardia ("VT") and atrial fibrillation ("AF"), today announced CE Mark approval of its ultra-low temperature cryoablation ("ULTC") system for the treatment of monomorphic ventricular tachycardia. The system consists of the upgraded cryoablation console, also capable of supporting atrial ablation procedures using commercially available iCLAS™ catheters, and the vCLAS™ ventricular cryoablation catheter
Adagio Medical, Inc.: Adagio Medical Announces CE Mark approval of VT Cryoablation System, Plans for Immediate Commercialization in Select European Centers finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Autism Foundation's World Autism Awareness Day Events Revealed chronicle.lu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chronicle.lu Daily Mail and Mail on Sunday newspapers.
In the EU-PORIA real-world registry of patients with atrial fibrillation who underwent pulsed field ablation, most patients did not have recurrence at 1 year and the learning curve for operators was quick. “EU-PORIA reflects data coming from seven European centers,” Boris Schmidt, MD, professor of medicine at Cardioangiologisches Centrum Bethanien in Frankfurt, Germany, told Healio.